ArticleArthritis research & therapy2026
Identification of candidate biomarkers for diagnosis, disease activity, and relapse prediction in IgG4-related disease.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectivesIgG4-related disease (IgG4-RD) is an immune-mediated condition with diagnostic challenges in clinical practice. Sensitive biomarkers are needed for diagnosis, disease activity and disease progression assessment. This study aimed to identify and validate novel serum protein biomarkers of IgG4-RD to improve clinical management.
methodsUsing Olink proteomics, we analyzed the expression of 92 serum immuno-oncology-related proteins in 11 treatment-naïve IgG4-RD patients and 11 healthy controls (HCs). Candidate biomarkers capable of distinguishing IgG4-RD patients from HC were subsequently validated by enzyme-linked immunosorbent assay in a large independent cohort (n = 220). Diagnostic performance was assessed via 5-fold cross-validation. Correlations between biomarkers and clinical characteristics were also investigated, as well as predictive value for disease relapse.
resultsOlink proteomic analysis identified 27 differentially expressed proteins between IgG4-RD and HCs. Through longitudinal follow-up, serum PD1, OX40, CCL19, and MMP12 were significantly upregulated in IgG4-RD patients and closely associated with disease progression, serum IgG4 levels and inflammatory indicators. A comprehensive diagnostic model incorporating the four biomarkers was developed and showed high discriminatory capacity. Elevated baseline PD1 level served as an independent risk factor to predict clinical relapse of IgG4-RD patients.
conclusionThis study identifies four novel serum biomarkers that effectively assist diagnosis, assess disease activity, and one capable for clinical relapse prediction. These findings provide a practical approach for large-scale clinical screening and monitoring of IgG4-RD patients. Furthermore, the identified proteins may offer new insights into disease pathogenesis and represent potential therapeutic targets for this challenging condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.